[
  {
    "ts": null,
    "headline": "Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology",
    "summary": "NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced the appointment of Wolfgang Liedtke, MD PhD, as Senior Vice President, Global Head of Ne",
    "url": "https://finnhub.io/api/news?id=40b0aa42d494ae2ab7505a201d9d72c8f4189124e59f142d2e3ba2c0cc8e4a83",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767875400,
      "headline": "Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology",
      "id": 138036924,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced the appointment of Wolfgang Liedtke, MD PhD, as Senior Vice President, Global Head of Ne",
      "url": "https://finnhub.io/api/news?id=40b0aa42d494ae2ab7505a201d9d72c8f4189124e59f142d2e3ba2c0cc8e4a83"
    }
  },
  {
    "ts": null,
    "headline": "Upstream Bio: Fully Priced After Recent Rally",
    "summary": "Upstream Bio, Inc. surged on Phase 2 verekitug data for CRSwNP, but revenue likely post-2030 and dilution risk remains. Click for more on UPB stock prospects.",
    "url": "https://finnhub.io/api/news?id=ea6b0946b33801fc42d573d7c7f62f7d8feed18e036f9db7e9f6d5d9f62097fd",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767872639,
      "headline": "Upstream Bio: Fully Priced After Recent Rally",
      "id": 138037586,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2009511438/image_2009511438.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Upstream Bio, Inc. surged on Phase 2 verekitug data for CRSwNP, but revenue likely post-2030 and dilution risk remains. Click for more on UPB stock prospects.",
      "url": "https://finnhub.io/api/news?id=ea6b0946b33801fc42d573d7c7f62f7d8feed18e036f9db7e9f6d5d9f62097fd"
    }
  }
]